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Kidney disease is becoming increasingly common in CF. This review looks at the effect of CFTR on the kidney, the problems with measuring
renal function effectively in CF, the causes and incidence of renal dysfunction, and its pathophysiology. Strategies to reduce aminoglycoside
toxicity are discussed.
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Cystic fibrosis is one of the success stories of modern
medicine — whereas in the 1950s most individuals with theby Elsevier B.V. All rights reserved.
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born in the 21st century will live into their fifth or sixth decade.
Indeed, the latest UK CF Registry (capturing nearly all the
UK's N9000 patients) indicates that the median survival is
already over 41 years, and very few patients die in childhood.
Furthermore, many adolescents transitioning to the adult sector
can now expect to have normal or near-normal lung function,
attributed to better therapy, organisation of care, and improving
socio-economic factors.
However, the ageing of the CF population has brought with
it unforeseen problems and complications and there has been a
paradigm shift in outlook in the adult healthcare sector, from a
focus on the care of lung disease to the management of a
complex multi-system chronic illness. One of these complica-
tions has been the emergence of the involvement of the kidney
in the CF condition. Although CFTR is found in the kidney,
mainly in the proximal and distal tubules, and its inactivation
can cause low molecular weight proteinuria [1], its exact
role and effect in CF related kidney disease is unknown and
primary renal disease is an unusual feature, in contrast to
secondary renal dysfunction that is becoming increasingly
common. Nephrogenesis is completed by thirty-six weeks of
gestation [2]: nephron numbers are genetically determined
(the human average is 1 million per kidney) and they do not
regenerate. Following birth, there is a gradual decline in
their number, but the attrition rate is accelerated by chronic
infection, diabetes, and vascular disease, all of which can be
present in CF.
Furthermore, CF individuals are in danger of acute kidney
injury and the development of chronic renal disease through
exposure to multiple potentially nephrotoxic agents includ-
ing aminoglycosides, non-steroidal anti-inflammatory drugs
(NSAIDs) and immune-suppressants. Nephropathy can also
result from abnormalities in salt transport [3], colonisation with
Pseudomonas aeruginosa (Psa) [4], and the development of
Cystic Fibrosis Related Diabetes (CFRD) requiring insulin [5].
This paper reviews the problems with measuring renal
dysfunction in CF, its patho-physiology, and discusses reno-
protective strategies in order to decrease the incidence of this
important complication.
2. Diagnosis and screening of renal dysfunction
Renal blood flow, glomerular filtration, and tubular resorptive
capacity all play their part in defining renal function. In humans,
the assessment of renal function is limited to measuring the
Glomerular Filtration Rate (GFR), renal blood flow, and estimation
and measurement of proteinuria and creatinine clearance derived
from various formulae.
Although GFR has always been considered the best clinical
estimate of renal function and correlates well with both
clinical severity and disturbances in renal function [6], it has
its limitations. It cannot be assessed directly and is determined
indirectly by measuring the clearance of suitable filtration
markers that are not reabsorbed, secreted or metabolised by
the kidney, such as Cr-EDTA, inulin, 99Tc-DTPA and iohexol
[7]. However, tests involving these markers are costly, timeconsuming, need intravenous infusions and accurate sample
collection, all of which are problematic. Also, many CF patients do
not have normal or stable serum creatinine levels, which further
complicates its measurement.
GFR is also insensitive in the detection of early renal
dysfunction: up to 30% of nephrons can cease to function before
GFR alters, since the remainder compensate by increasing their
filtration rate [8,9]. It is only with a further loss of renal tissue that
GFR will reduce.
Due to the difficulty of directly measuring GFR, indirect
methods based on the clearance of physiological products
through the kidney have been devised. One such test is the
clearance of creatinine (CCl). Creatinine, a muscle breakdown
product, is produced in a predictable way in stable individuals
and is only minimally reabsorbed by the renal tubules. However,
because the measurement of CCl depends upon the accurate urine
collection, it is subject to error in adults and impractical in young
children, a number of formulae based on serum creatinine, muscle
mass, and physical constants have been devised to estimate it
(eCCL).
Formulae including the abbreviated Modification of Diet in
Renal Disease (aMDRD) equation [10] and the Cockcroft-Gault
formula (CGF) [11] are widely used clinically and have been
advocated in those with CF [12]. However although these
formulae are simple to use in daily practice, they are not reliable
when the serum creatinine is unstable, overestimating CCl and
therefore GFR when the creatinine is rising, and vice versa
[13,14]. They have not been validated in CF and furthermore, this
lack of validation is particularly important because many CF
patients are in a hypermetabolic state [15], have diminished
muscle mass, and have limited exercise capacity [16], all of
which can influence creatinine production.
Data published from our own unit [17] comparing 74 adult CF
patients with no previous history of renal problems and a normal
range of serum creatinine, with 29 healthy age and BMI matched
control subjects, showed these formulae to be unreliable.Measured
creatinine clearance was compared with eCCL using various
formulae: all (including the popular CGF and aMDRD-derived
estimates) compared less favourably in CF patients than controls
and grossly over-estimated renal function in CF patients with
reduced CCl (b80 ml/min)[Table 1]. These formulae should be
used and interpreted with caution in CF patients; generally they
overestimate creatinine clearance and therefore understate the
degree of renal dysfunction in the CF population.
Drugs such as aminoglycosides can cause proximal tubular
damage, leading to acute tubular necrosis resulting in electrolyte
leak from a defect in the urinary concentrating capacity and the
elevated urinary excretion of certain tubular enzymes.
Hence over the past 40 years attention has been directed
towards the evaluation of urinary enzymes as non-invasive
biomarkers of renal tubular damage. They can be sensitive tools
useful in the early diagnosis of acute renal injury before
conventional laboratory assays become deranged [18–20], and
they reflect sub-clinical toxicity and might have an important role
in screening for early renal damage. They may also indicate the
site of primary tubular damage because of their localisation in
tubular lysosomes (N-acetyl-β-D-glucose-aminidase [NAG]) and
Table 1
Comparison of mCCL and eCCL (CGF and abbreviated MDRD [4 variable]) in renally impaired CF patients (mCCL b 80 ml/min).
Reprinted from J Cyst Fibros 2007 Jan;6(1):41–7. M. Al-Aloul,M. Jackson,G. Bell,M. Ledson,M. Walshaw. Comparison of methods of assessment of renal function
in cystic fibrosis (CF) patients. License Mar 08, 2013 with permission from Elsevier.
n Mean mCCL (S.D.) eCCL formula Mean eCCL (S.D.) % eCCL within 33% of mCCL Bias 95% CI for bias LOA
mCCL b 80 35 63.5 (12.3) CGF 81.7 (18.1) 60% 18.3 13.6 to 23 −9.7 to 46.3
aMDRD 79.3 (20.2) 65% 15.8 10.5 to 22.0 −17.5 to 50.1
mCCL ≥ 80 39 100.7 (13.8) CGF 102.3 (16.6) 95% 1.6 −3.5 to 6.7 −30.4 to 33.6
aMDRD 95.1 (16.1) 84% −5.6 −11.1 to −0.1 −39.6 to 28.4
Total 74 83.1 (22.9) CGF 92.6 (20.1) 78% 9.7 5.5 to 13.5 −24.9 to 43.9
aMDRD 88 (19.7) 77% 4.9 0.3 to 9.5 −35.3 to 45.1
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urinary NAG excretion during IV aminoglycoside therapy in
patients with CF has been reported [21,22] and 1 study [21]
demonstrated a rise in AAP following IV tobramycin.
Other markers including neutrophil gelatinase-associated
lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) are
considered indicators of acute kidney insult [23,24]. Unfortunate-
ly NGAL is also produced in response to damaged epithelial cells
in the lung [25], effectively excluding its use in the CF condition.
Recent interest in urinary KIM-1 as a marker of renal necrosis and
regeneration has not been fully evaluated [26] and there have been
no studies of its use in CF.
A newer marker used over the last decade to evaluate renal
function is cystatin C [27], a protein that undergoes free
glomerular filtration before metabolism by the proximal tubule;
serum concentrations are mainly determined by glomerular
filtration, making it a useful endogenous marker. However it
has not been fully evaluated in CF and the results of the small
number of studies have been conflicting. Beringer et al. [28]
and Halacova et al. [29] suggested some superiority of this
measure but Soulsby et al. [30] in their study of 47 adult and
paediatric patients did not find any statistical benefit over any
other method of estimating renal function and larger adequately
powered studies are needed to validate the role of this marker in
CF.
3. Drug related renal problems
CF patients are constantly exposed to pharmacological
agents, many administered in higher doses due to an increase
in metabolic activity and drug metabolism. Such nephrotoxic
drugs that might be prescribed include NSAIDs, ciprofloxacin,
colistin, azithromycin, ceftazidime, proton pump inhibitors,
sulphonamides, rifampicin and diuretics. In many cases, any
resulting renal insult is idiosyncratic or unpredictable, but
there are 2 groups that most commonly cause renal dysfunction
in CF-aminoglycosides and post-transplant immune-suppressive
therapy.
3.1. The role of aminoglycosides in renal dysfunction in CF
Aminoglycosides are commonly used in the treatment of
gram-negative diseases including pseudomonal infections. These
agents are lipid and water-soluble molecules that following IV
administration have a rapid compartmental distribution and achievepeak serum levels within 30 min. Many are highly effective
against Psa, are relatively cheap compared to other classes of
antibiotics and widely used in CF. Activity is related to their
peak levels and also the post-antibiotic effect (a continuing
bactericidal action when the drug is no longer detectable).
However, since CF patients have an accelerated renal
clearance and altered pharmacokinetics [31] high doses of
intravenous antibiotics need to be administered (3–5 mg
aminoglycoside/kg body weight/dose) to achieve therapeutic
concentrations. Aminoglycosides do not bind well to plasma
proteins and are eliminated via glomerular filtration: up to
15% of the filtered dose is reabsorbed by the proximal tubule
through a saturable mechanism, which once exceeded results
in the disruption of lysosomal function by binding to brush
border membranes and subsequent cellular apoptosis [32,33].
Aminoglycoside induced nephrotoxicity is a dose-limiting feature,
and unfortunately toxic levels are close to the therapeutic range
[34].
In a study of 80 stable CF adults chronically infected with
Psa and no previous history of renal disease [35] we showed
an association between lifetime intravenous aminoglycoside
exposure and reduced renal function. Recently, this was
confirmed by Jain et al. [36] who suggested that renal
hyper-filtration may also play a part in CF. In our study, up
to 42% had CCl below the normal range (determined by the
CGF and 24 h urine collection) and there was a strong
correlation (r = −0.32, p = 0.0055) between aminoglycoside
use and diminishing renal function [Fig. 1]. Interestingly, this
relationship was potentiated by the co-administration of
intravenous colistin (r = −0.42, p b 0.0002), but there was
no correlation with colistin when used in combination with other
antibiotics alone. Unfortunately, the emergence of multi-resistant
epidemic strains of Psa, such as the Liverpool epidemic strain,
often sensitive only to aminoglycosides and colistin, means those
chronically infected with such strains frequently require repeated
courses of these toxic antibiotics for good clinical reasons.
Some paediatric centres administer routine 3-monthly
intravenous anti-pseudomonal antibiotic therapy, including an
aminoglycoside, in an attempt to maintain lung function and
prevent pulmonary exacerbations. This increases the lifetime
exposure to these toxic drugs, exacerbates the development of
resistance patterns [37], has not been shown to confer any benefit
in pulmonary function [38], and may be associated with higher
mortality [39]. The potential short-term benefit does not outweigh
the propensity for long term renal damage.
Fig. 1. Correlation between renal function (mCCl) and lifetime use of IV nephrotoxic antibiotics.
Reproduced from Pediatr Pulmonol 2005 Jan;39(1):15–20 with permission of John Wiley & Sons, Inc.
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Although the obvious way to diminish toxicity would be to
reduce or eliminate aminoglycoside use, this is not practicable
as these drugs are not only effective against Psa, but also cheap
and familiar to many CF clinicians. There are several ways in
which their toxic effects can be limited:
3.3. Dosing intervals
One strategy is to give more aminoglycoside less frequently.
Increasing the dosing interval will reduce the basal serum
aminoglycoside level and the accumulation of the drug within
the kidney, whilst theoretically still allowing the high peak
serum levels and post-antibiotic effect to potentiate bacterial
killing (Fig. 2) [40]. Adeboyeku et al. [41] showed that twice
daily dosing of tobramycin and ceftazidime was comparable toFig. 2. Effects of saturable uptake on kidney cortical accum
Reproduced from [Thorax, Prayle A,WatsonA, FortnumH, Sthrice daily dosing in 146 CF patients. Although a number of
studies comparing treatment outcomes and side-effects of a
once daily dosing regimen did not show benefit [42–44], the
TOPIC trial [43] demonstrated equal efficacy between once and
thrice daily tobramycin when administered with thrice daily
ceftazidime and based on urinary marker analysis there was
also less acute renal damage in children, but no difference was
shown in adult patients.
Many centres now give aminoglycosides once daily, on the
basis of convenience in adults, since it reduces the complexity
of drug level monitoring [45]. This is reflected in the US
guidelines [46] where a once daily dosing is preferred but the
UK guidance [47] includes either a once or thrice daily dosing
schedule when aminoglycosides are used in the treatment of
pulmonary exacerbations.
Since the toxicity of aminoglycosides varies with renal
clearance and is dose dependent, serum peak and trough levelsulation in single daily versus three times daily dosing.
myth A., Jul;65(7):654–8, 2010] with permission fromBMJ Publishing Group Ltd.
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therapeutic and non-toxic ranges. Optimum peak serum levels
for tobramycin (measured half an hour after completion of an
IV dose) are 8–12 mg/l, and b1 mg/l for the trough dose [47].
Where once daily dosing is used, only the trough level is
measured [47,48].
3.4. Dosing route
A further strategy to diminish nephrotoxicity is to optimise the
route of administration by the use of nebulised therapy. High
dose nebulised versions of tobramycin, currently available for the
prophylactic suppression of chronic pseudomonas infection in
CF patients, have excellent lung deposition, low systemic
penetration (12%) and higher sputum levels than IV preparations.
However, the role of nebulised tobramycin as a renal sparing
alternative to the IV form in the treatment of acute respiratory
exacerbations in CF patients has not been well explored.
In a pilot randomised crossover trial in 14 adult CF patients
[49], during a respiratory exacerbation we gave Tobramycin
Nebulised Solution (TNS) at a standard CF dose of 300 mg bid in
conjunction with another IV antibiotic and compared it with the
IV preparation. Although the mean improvement in spirometry
was similar in both arms, there was much less expression of
markers of acute renal injury in the urine [Table 2] in the TNS
arm. This suggests that TNS is effective in treating acute
pulmonary exacerbations in CF, but causes less acute renal
damage than the IV preparation. This mode of administration
needs further exploration and larger suitably powered studies
are now required to confirm this effect and how it relates to
long-term nephrotoxicity.
Nevertheless, even inhaled antibiotics reach significant serum
levels and acute renal failure can occur with both nebulised
tobramycin [50] and colistin [51].
3.5. Competitive inhibition
Agents which compete for the renal binding sites may reduce
the toxic effects of aminoglycosides. One such drug is fosfomycin
(1,2-epoxy-propyl-phosphonic acid). Animal studies have shown
that it may protect against aminoglycoside nephrotoxicity by
competing for the binding site within the proximal tubular cell,
therefore preventing cellular apoptosis. Isolated in 1969 from
Streptomyces fradiae [52] and now produced synthetically, it is
unique andwas first used in patients with CF in 1984 [53]. After IV
administration 90% is excreted unchanged through the kidneyTable 2
Urinary biochemical markers following administration of nebulised and IV tobramy
(Adapted): Reproduced with permission of John Wiley & Sons, Inc. Pediatric Pulm
Urinary marker (log10) High dose nebulised
tobramycin
IV tobramycin
Mean change SD Mean change
NAG (iu/mmol) 0.02 0.51 0.74
AAP (iu/mmol) −0.37 0.69 0.82
α-GST (mcg/mmol) 0.01 0.06 0.99
Collagen IV (mcg/mmol) −0.08 −0.01 0.38within 24 h. Not bound to serum proteins, it has a half life of 1.5–
2 h, with a large volume of distribution and diffuses well into lung
tissue [54]. It is well tolerated by CF patients [55] and has the
added benefit of possessing effective anti-pseudomonal properties.
In a pilot prospective randomised crossover trial we examined
this effect in CF [56] and showed that the addition of IV
fosfomycin in 8 adult CF patients during acute exacerbations
reduced the urinary levels of renal tubular enzymes elevated by
IV tobramycin, suggesting that it may protect the lysosomal
membrane and hence renal function. Larger studies are required
to confirm this effect.
4. Aminoglycosides and acute renal failure in CF
Although episodes of acute renal failure (ARF) can occur
with inhaled preparations, they are more commonly associated
with intravenous therapy [50,57,58].
We reported 8 cases of ARF in adult CF patients from our
centre [59], implicating intravenous tobramycin and a later survey
of 55 UK CF centres [57] found up to 10.5 cases ARF/10,000 CF
patients/year. However, few reports were obtained from adult
centres, suggesting that the true incidence may be much higher. In
88% of cases aminoglycosides (76% — gentamicin) were
prescribed at the onset of ARF or within the preceding week, and
where renal biopsy was performed, 85% demonstrated acute
tubular necrosis (all having received gentamicin). Half required
renal dialysis and a complete recovery was seen in 92%.
Gentamicin, commonly used in paediatric CF practice is more
nephrotoxic than other aminoglycosides. Its structure (two amino
sugars joined to a hexose nucleus) reduces its absorbability and
its subsequent accumulation potentiates tubular necrosis and
ultimately renal dysfunction [60]— it should not be used in CF
patients.
5. Immuno-suppression post-transplant
Survival following lung transplantation has improved consid-
erably over the last two decades, and in CF up to 50% can expect
to survive for more than 7 years [61]. However, they can also
expect to develop a life-time of transplant related complica-
tions, either related to rejection or the toxic effects of immune
suppressive therapy and renal dysfunction is well-recognised
as part of this spectrum, occurring in up to 35% of all lung
transplant recipients [61].
Calcineurin inhibitors including cyclosporine impair endothe-
lial cell function, with a subsequent decrease in the production ofcin.
onology 38[S27], P179. 2004.
Mean diff between
treatments
95% CI p value
SD
0.44 −0.72 −1.11 to −0.33 0.004
0.62 −1.19 −1.72 to −0.66 0.0003
0.90 −0.99 −1.47 to −0.51 0.001
0.36 −0.46 −0.83 to −0.08 0.04
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resultant increased release of endothelin and thromboxane, both
potent vasoconstrictors [62,63] and can cause vasoconstriction of
the afferent and efferent glomerular arterioles [64]. This leads
to reduction in renal blood flow and GFR contributing to the
development of renal failure [65,66]. In addition, there have been
reports of calcineurin inhibitor toxicity and associated haemolytic
uraemic syndrome (HUS) following lung transplantation in this
patient group [67].
In recently published data using eGFR, an analysis of 993
adult lung transplant recipients from the US CF Foundation
Patient Registry (2000–2008) [68] showed that significant
renal dysfunction increased over time, and this worsened with
age and in females. Overall, renal dysfunction (equivalent to at
least stage 3 chronic kidney disease) was common with a 2 year
and 5 year risk of 35 and 58% respectively, with 10% eventually
requiring haemodialysis. Although no association was found
with antibiotics, the results were extracted from registry data
where aminoglycoside use was not well recorded.
Furthermore, those with Cystic Fibrosis Related Diabetes
(CFRD) requiring insulin had a significantly higher risk of
developing post-transplant renal dysfunction similar to the
post-transplant renal complications in non-CF diabetes mellitus
[69], emphasising the importance of early and aggressive man-
agement of CFRD to minimise the long-term risks.
6. Other renal problems in CF
Despite the problems inherent in measuring renal function in
CF and problems with nephrotoxic drugs there is increasing
evidence of other renal pathologies in the CF patient population.
These are illustrated briefly below.
6.1. Nephrolithiasis
Low urine volume associated with salt depletion and
dehydration, hyper-oxaluria, hyper-uricosuria and hyper-calciuria
[70] all occur in CF and contribute to increased nephrolithiasis and
nephrocalcinosis, which has been found in 90% of autopsies [70].
Furosemide and prednisolone are associated with hyper-calciuria
and the prolonged episodes of immobilisation that can occur in CF
result in hyper-calcemia and hyper-calciuria.
Importantly, repeated antibiotic use leads to the destruction
of intestinal oxalate degrading bacteria such as Oxalobacter
formigenes, with the subsequent absorption of gut oxalates
which are then re-excreted through the kidney with resulting
crystallisation and oxalate stone formation. The incidence of
renal stones is up to 6% [71–74] compared to b2% in healthy
matched controls [75].
6.2. Amyloidosis
Secondary amyloidosis occurs as a result of chronic infection
and inflammation where it can cause the nephrotic syndrome
[76,77]. Although colchicine may confer benefit [78], the
prognosis is poor with most cases dying within one year. It is
increasingly being recognised in CF.6.3. IgA nephropathy
High levels of IgA are present in the circulation in CF
patients, presumably because of recurrent infections and
chronic inflammation. Deposition of this increased IgA in
the kidney can cause further immune activation leading to
glomerulonephritis. In addition the presence of liver disease
in CF, impairs immune complex clearance and increases the
risk of renal deposition [79]. IgA nephropathy is associated
with many autoimmune conditions: when CF is also present
the prognosis is poor, with 25% mortality. It remains the most
commonly reported cause of glomerulonephritis in CF patients
[80], present in up to 80% of cases where renal biopsy was
performed [81].
7. Cystic Fibrosis Related Diabetes Mellitus (CFRD)
CFRD, discussed as a separate review in this series, is unique
and distinct: although uncommon in childhood, its prevalence
increases with age and it affects up to 50% of adults [82]. Despite
the fact that it is a risk factor for the development of chronic
kidney disease compounded by increasing age, worse pulmonary
function, malnutrition, liver dysfunction and steroid use [83] in
these patients, few studies have investigated it.
Although assessment of US CFF Registry data over a 10 year
period found a 2.3% annual prevalence of at least stage 3 kidney
disease which doubled with every 10 years of life and with the
diagnosis of CFRD [5], this should be viewed with caution since
the definition of renal function was based on eGFR, which
underestimates the degree of renal damage in CF. Further studies
are needed to assess the impact of this increasingly common renal
complication in CF.
The lack of a satisfactory screening tool for diabetes in this
susceptible population means that the renal consequences of this
commonCF complicationmay be underplayed. Current guidance
[84,85] recommends an oral glucose tolerance test (OGTT)
for the diagnosis of diabetes mellitus where the thresholds for
significant glucose intolerance are drawn from a non-CF diabetic
population at risk of developing micro-vascular complications
with non-CF specific outcomes. In CF different complications
occur early and better methods to make an early diagnosis of
CFRD are needed.
One such method is ambulatory Continuous Glucose Monitor-
ing (CGM), a stronger predictor of the development of CFRD than
the OGTT [86] and we have demonstrated it to be a valuable
screening test for CFRD [87].
In the non-CF population, micro-albuminuria (defined as
a persistent urine albumin level of N15 mg/l or an albumin-
creatinine ratio (ACR)≥2.5 mg/mmol in males and 3.5 mg/mmol
in females) can be used as an indicator of renal damage. Although
microalbuminuria occurs in CFRD [88], its use in CF has been
questioned due to the possible contributory role of other factors—
chronic infection with repeated use of potentially nephrotoxic
drugs, sepsis and acute dehydration, and it may well be a less
sensitive indicator of progression to diabetic nephropathy.
Micro-vascular complications similar to those seen in Type
1 diabetes do occur in CFRD, but with a lower prevalence of
315D. Nazareth, M. Walshaw / Journal of Cystic Fibrosis 12 (2013) 309–317retinopathy and a higher prevalence of microalbuminuria [89]:
this is likely to increase over the coming decades, as the CF
population ages.
8. Future perspectives
As CF patients age and have an increased lifetime exposure to
potentially nephrotoxic therapy and worsening glucose intoler-
ance, renal disease is now more commonly recognised as a
feature of CF.
However, assessment of renal dysfunction in CF is hampered
by the lack of suitable monitoring tests of renal function. The
focus of new antibiotic development remains on chronic infection
with Psa, still the main pathogen leading to advanced CF lung
disease. With the problems of multi-resistant Psa species and
those associated with aminoglycosides, there is a need for
other antibiotics that possess anti-pseudomonal activity and
an increased need for new approaches in the treatment of
pulmonary infection. Strategies to limit the effect of nephrotoxic
drugs, particularly aminoglycosides, and the early recognition of
CFRD and its timely treatment to prevent renal complications
will need to be further developed.
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